Abstracts tagged "psoriatic arthritis and treatment"

Abstract Number: 1601 • 2018 ACR/ARHP Annual Meeting
Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis: Results from a Cross-Sectional Observational Study in the United States
Philip J. Mease¹, Clive Liu², Evan Siegel^3,4, Heather Richmond⁵, Meijing Wu⁶, Liang Chen⁶, Kevin Douglas⁶ and Benjamin Lockshin⁷, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Bellevue Dermatology Clinic, Bellevue, WA, ³Georgetown University, Washington, DC, ⁴Arthritis and Rheumatism Associates, Rockville, MD, ⁵Clear Dermatology, Houston, TX, ⁶AbbVie Inc., North Chicago, IL, ⁷US Dermatology Partners, Rockville, MD
Background/Purpose: In patients (pts) with psoriatic arthritis (PsA), early diagnosis and effective treatment has been shown to decrease functional disability and structural progression (Gladman DD,…
Abstract Number: 2073 • 2018 ACR/ARHP Annual Meeting
Role of miRNA-21-5p As a Potential Biomarker for the Inflammation Pathway in Psoriatic Disease and Response to Methotrexate Treatment
Rohan Machhar¹, Justine Y. Ye², Vinod Chandran² and Dafna D Gladman³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. miRNAs are small non coding RNAs whose main function, at a post…
Abstract Number: 2626 • 2018 ACR/ARHP Annual Meeting
Normalization of CRP Levels and Clinical Response to Ixekizumab in Patients with Psoriatic Arthritis: Results from the Spirit Studies
Bernard Combe¹, Paul Emery², Annelies Boonen³, Soyi Liu Leage⁴, Christophe Sapin⁴, Natalia Bello⁵ and Maxime Dougados⁶, ¹CHU, Montpellier University, Montpelier, France, Montpellier, France, ²Leeds Musculoskeletal Biomedical Research Unit, LTHT Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ³Division of Rheumatology, Maastricht University, School for Public Health and Primary Care, Maastricht University Medical Centre, The Netherlands, Maastricht, Netherlands, ⁴Lilly France, Neuilly sur Seine Cedex, France, Neuilly sur Seine Cedex, France, ⁵Eli Lilly and Company (Spain), Alcobendas, Spain, Alcobendas, Spain, ⁶Rheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France, Paris, France
Background/Purpose: It is important to understand the association between early changes in inflammatory biomarkers and treatment response at later times after initiation of a biologic…
Abstract Number: 611 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Early Adalimumab Therapy in Psoriatic Arthritis Patients from Reuma.Pt
Helena Santos¹, Mónica Eusébio², Joana Borges³, Diana Gonçalves⁴, Pedro Ávila-Ribeiro⁵, Daniela Santos Faria⁶, Carina Lopes⁷, João Rovisco⁸, Ana Águeda⁹, Patrícia Nero¹⁰, Paula Valente¹¹, Ana Rita Cravo¹² and Maria José Santos¹³, ¹Instituto Português de Reumatologia, Lisbon, Portugal, ²Sociedade Portuguesa de Reumatologia, LIsboa, Portugal, ³Instituto Português de Reumatologia, Lisboa, Portugal, ⁴Centro Hospitalar de São João, Coimbra, Portugal, ⁵Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁶ULSAM, Ponte de Lima, Portugal, ⁷Hospital de Egas Moniz-CHLO, Lisbon, Portugal, ⁸Centro Hospitalar e Universitário de Coimbra, Lisbon, Portugal, ⁹Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ¹⁰Hospital CUF Descobertas, Lisbon, Portugal, ¹¹Centro Hospitalar Entre o Douro e Vouga, Lisbon, Portugal, ¹²Medical, AbbVie, Lisbon, Portugal, ¹³Reuma.pt, Almada, Portugal, Almada, Portugal
Background/Purpose: There is a lack of evidence on the effect of biologics in early treatment of psoriatic arthritis (PsA) patients (Pts). Benefit of concomitant use…
Abstract Number: 881 • 2017 ACR/ARHP Annual Meeting
Ustekinumab Is Superior to TNF Inhibitor Treatment in Resolving Enthesitis in Psa Patients with Active Enthesitis- Results from the Enthesial Clearance in Psoriatic Arthritis Study
Elizabeth G. Araujo¹, Matthias Englbrecht², Sabrina Hoepken¹, Stephanie Finzel³, Axel J. Hueber², Juergen Rech⁴ and Georg Schett¹, ¹Rheumatology and Immunology, Department of Internal Medicine 3, Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Freiburg, Germany, ⁴Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany
Background/Purpose: IL-23 is considered to play an important role in the development of enthesitis. Ustekinumab (UST), a combined inhibitor of IL-12/IL-23 shows efficacy in psoriatic…
Abstract Number: 1518 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol Effectiveness and Retention Rate in Psoriatic Arthritis. Real Life Data
Arantxa Conesa¹, Manuel Fernández², Rosa Expósito³, Jose Campos⁴, Jose Ramon Lamua⁵, Maria del Pilar Navarro⁶, Paula Rubio-Muñoz⁷, Pilar Ahijado-Guzman⁸ and Carlos M Gonzalez⁹, ¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ²Hospital Universitario de Guadalajara, Guadalajara, Spain, ³Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ⁴Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁵Hospital del Henares, Madrid, Spain, ⁶Hospital de Fuenlabrada, Fuenlabrada, Spain, ⁷Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁸Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, ⁹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: To evaluate the effectiveness and safety of Certolizumab Pegol (CZP) in a real word setting in Psoriatic Arthritis (PsA) patients. Methods: Multicentric cohort of…
Abstract Number: 1557 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Psoriatic Arthritis: Experience from a Real-World Setting
Martin Brom¹, Sebastian Moyano¹, Florencia Beatriz Mollerach², Luciano Fernando Lo Giudice³, Maria Laura Acosta Felquer¹, Marina Scolnik⁴, Santiago Ruta⁴ and Enrique R Soriano⁵, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology section, Internal Medicine Unit, Hospital Italiano de Buenos Aires and Fundacion PM Catoggio, CABA, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ⁵Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Both EULAR (European League Against Rheumatism) and GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) recently published treatment guidelines for Psoriatic…
Abstract Number: 1673 • 2016 ACR/ARHP Annual Meeting
Characteristic Phenotypes of Peripheral T Cells and Efficacy of Biological Dmards in Patients with Psoriatic Arthritis
Ippei Miyagawa¹, Shingo Nakayamada², Satoshi Kubo³, Kazuhisa Nakano², Yusuke Miyazaki³, Maiko Yoshikawa⁴ and Yoshiya Tanaka⁵, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Biological DMARDs (bDMARDs) such as adalimumab (ADA), infliximab (IFX), ustekinumab (UST) and secukinumab (SEC) become available and efficacious in patients with psoriatic arthritis (PsA).…
Abstract Number: 1679 • 2016 ACR/ARHP Annual Meeting
Predictors of Persistency with TNFi in Biologic-Experienced Versus Biologic-Naive Psa Patients Enrolled in the Corrona Registry
CJ Etzel¹, Bradley S. Stolshek², Sabrina Rebello³, David Collier⁴, Alex Mutebi⁵, Sally W Wade⁶, Wendi Malley⁷, JD Greenberg⁷ and Leslie R Harrold⁸, ¹The University of Texas MD Anderson Cancer Center, Houston, TX, ²Amgen, Thousand Oaks, CA, ³Epidemiology, Corrona, LLC, Southborough, MA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Global Health Economics, Amgen, Thousand Oaks, CA, ⁶Wade Outcomes Research and Consulting, Salt Lake City, UT, ⁷Corrona, LLC, Southborough, MA, ⁸UMass Medical School, Worcester, MA
Background/Purpose: Little is known about factors associated with persistency of TNFi use among biologic-naïve and biologic-experienced Psoriatic Arthritis (PsA) patients in routine clinical practice in…
Abstract Number: 1691 • 2016 ACR/ARHP Annual Meeting
The Comparative Immunogenicity of Biologic Therapy and Its Clinical Relevance in Psoriatic Arthritis: A Systematic Review of the Literature
Alejandro Balsa¹, Sadiq Lula², Lisa Marshall³, Piotr Szczypa⁴ and Laraine Aikman⁵, ¹Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain, ²Envision Pharma Group, London, United Kingdom, ³Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁴Pfizer Ltd, Sandwich, United Kingdom, ⁵Pfizer Ltd, Walton Oaks, United Kingdom
Background/Purpose: Anti-inflammatory biologic agents have been shown to provide significant benefit in controlling disease activity in psoriatic arthritis (PsA) and inhibiting progression of joint damage.…
Abstract Number: 1719 • 2016 ACR/ARHP Annual Meeting
Secular Trends in Treatment Patterns for Psoriasis and Psoriatic Arthritis: A Population-Based Cohort Study
Joseph F Merola¹, Joyce Lii², Rishi J. Desai³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medicine, Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are complex, multi-system diseases for which an ever-increasing landscape of therapies exists. Little is known about the population…
Abstract Number: 2232 • 2016 ACR/ARHP Annual Meeting
Above-Label Dosing with Biologics in Treatment-NaïVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis
Sergio Schwartzman¹, Yunfeng Li², Huanxue Zhou³, Vivian Herrera² and Jacqueline B. Palmer², ¹Hospital for Special Surgery, New York, NY, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³KMK Consulting Inc, East Hanover, NJ
Title: Above-Label Dosing with Biologics in Treatment-Naïve and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2…
Abstract Number: 2234 • 2016 ACR/ARHP Annual Meeting
Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis
Sergio Schwartzman¹, Yunfeng Li², Huanxue Zhou³, Vivian Herrera² and Jacqueline B. Palmer², ¹Hospital for Special Surgery, New York, NY, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³KMK Consulting Inc, East Hanover, NJ
Authors: S. Schwartzman*1, Y. Li2, H. Zhou3, V. Herrera2, J. Palmer2 Affiliations: 1Hospital for Special Surgery, New York, NY, US; 2Novartis Pharmaceuticals Corporation, East Hanover,…
Abstract Number: 2735 • 2016 ACR/ARHP Annual Meeting
Regional Variability of Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: An Analysis from a Prospective, Observational Registry
Proton Rahman¹, Dalton Sholter², Michelle Teo³, Regan Arendse⁴, Denis Choquette⁵, Mary Bell⁶, Angeliki Karellis⁷, Eliofotisti Psaradellis⁸, Francois Nantel⁹, Allen J Lehman¹⁰, Cathy Tkaczyk¹¹, Karina Maslova¹⁰ and Brendan Osborne¹¹, ¹Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴University of Saskatchewan, Saskatoon, ON, Canada, ⁵Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Department of Surgery, McGill University, Montreal, QC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Although remission remains the ultimate treatment goal in psoriatic arthritis (PsA) management, minimal disease activity (MDA), which encompasses remission and low disease activity, constitutes…
Abstract Number: 2757 • 2016 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: 104 Weeks Results from a Phase 3 Trial
Iain B McInnes¹, Philip J Mease², Christopher T. Ritchlin³, Proton Rahman⁴, Alice B Gottlieb⁵, Bruce Kirkham⁶, Radhika Kajekar⁷, Evie Maria Delicha⁸, Luminita Pricop⁹ and Shephard Mpofu⁸, ¹University of Glasgow, Glasgow, Great Britain, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁴Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁵Tufts University School of Medicine, Boston, MA, ⁶Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷One Health Plaza, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab, a fully human anti–IL-17A monoclonal antibody, significantly improved signs and symptoms of psoriatic arthritis (PsA) over 52 weeks (wks) in FUTURE 2 study (NCT01752634).1,2 Here…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].